Timber Pharmaceuticals Signs Waiver Agreement with Warrant Holders

November 22nd, 2020 11:56 am

WOODCLIFF LAKE, NJ, Nov. 20, 2020 (GLOBE NEWSWIRE) -- NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has signed waiver agreements with certain of its existing institutional investors.

Read more here:
Timber Pharmaceuticals Signs Waiver Agreement with Warrant Holders

Related Post

Comments are closed.


2021 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick